Identification of Polymorphisms Within the Vascular Endothelial Growth Factor (Vegf) Gene: Correlation With Variation in Vegf Protein Production

Watson, C. J.; Webb, Nicholas J.A.; Bottomley, M J; Brenchley, Paul

doi:10.1006/cyto.2000.0692

Cited by 662 publications

(691 citation statements)

References 12 publications

Supporting

Mentioning

643

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, our study is the first to show that the VEGF +405 C/C genotype, which has been previously reported to be associated with lower VEGF expression [42], may serve as a predictive factor of RIF after IVF.…”

Section: Discussionsupporting

confidence: 62%

“…As VEGF+405C/C genotype is associated with lower VEGF expression [42], our data suggest that this genotype hampers angiogenesis and embryo invasion and thus predisposes women included in an ICSI program to RIF. Furthermore, in early pregnancy, peripheral blood mononuclear cells (PBMCs) regulate (along with hCG) corpus luteum function after embryo implantation and thus directly affect embryo outgrowth into the endometrium.…”

Section: Discussionmentioning

confidence: 70%

“…The VEGF +405 G/C polymorphism is located within the 5′-untranslated region and leads to a difference in VEGF expression, with the lowest production observed for the C/C genotype [42]. This polymorphism may impact all VEGF mechanisms and it has been associated with susceptibility to many diseases [14,17,34,44].…”

Section: Discussionmentioning

confidence: 99%

“…Several single nucleotide polymorphisms (SNPs) have been found in the VEGF gene. Some SNPs (such as VEGF −2578 A/C (in the promoter region), −1154 G/A (also in the promoter region), +405 G/C (in the 5′-untranslated region) and 936 C/T (in the 3′-untranslated region)) are associated with altered VEGF expression [4,22,33,42]. Dysregulation of VEGF expression is implicated in many disease situations in which angiogenesis may be critical, such as breast cancer progression [17], cardiovascular disease [34], essential hypertension [14] and psoriasis [44].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The vascular endothelial growth factor (VEGF) +405 G/C polymorphism and its relationship with recurrent implantation failure in women in an IVF programme with ICSI

Boudjenah

Molina-Gomès

Wainer

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Successful embryo implantation depends on trophoblast proliferation, migration and, lastly, invasion of the endometrium (to anchor the trophoblast to the uterus). This invasion is mediated by locally produced soluble factors. Of these, vascular endothelial growth factor (VEGF) is the best characterized regulator of angiogenesis. Here, we investigate the association between the VEGF+405 C/G genotype and the recurrence of embryo implantation failure in women undergoing in vitro fertilization (IVF) program with intracytoplasmic sperm injection (ICSI). Methods Forty women with recurrent implantation failure defined by absence of pregnancy after transfer of more than 10 embryos and 131 women control, with at least one live birth after the transfer of fewer than 10 embryos were included. Genomic DNA was analysed with an allele-specific polymerase chain reaction and a Chi-2 test was used to compare the respective VEGF+405 C/G genotype frequencies in cases and controls. Results The frequency of the VEGF +405C/C genotype was higher in women with recurrent implantation failure after ICSI-embryo transfer than in controls (17.5 % and 5.3 %, respectively, p00.01). Conclusion The VEGF +405 G/C polymorphism may influence embryo implantation and VEGF+405 C/C genotype may predispose to recurrent implantation failure after ICSI-ET.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The vascular endothelial growth factor (VEGF) +405 G/C polymorphism and its relationship with recurrent implantation failure in women in an IVF programme with ICSI

Boudjenah

Molina-Gomès

Wainer

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…The vascular endothelial growth factor (VEGF) is one of the most potent endothelial cell mitogens and plays an important role in angiogenesis (Roy, Bhardawaj, & Ylä‐Herttuala, 2006). The VEGF gene is located on chromosome 6p21.3 and more than 30 single‐nucleotide polymorphisms (SNPs) have been identified in this gene (Ku et al., 2005; Lin, Wu, Tsai, Chen, & Chen, 2003; Vincenti, Cassano, Rocchi, & Persico, 1996; Watson, Webb, Bottomley, & Brenchley, 2000). The VEGF +936 C/T polymorphism (rs3025039), is a common SNP located in the 3’ untranslated region, and C allele is associated with substantially increased serum VEGF levels when compared to the variant T allele (Krippl et al., 2003; Li et al., 2011; Renner, Kotschan, Hoffmann, Obermayer‐Pietsch, & Pilger, 2000; Watson et al., 2000).…”

Section: Introductionmentioning

confidence: 99%

Genetic alterations of IDH1 and Vegf in brain tumors

et al. 2017

View full text Add to dashboard Cite

BackgroundThis study evaluates the presence of R132H mutation in isocitrate dehydrogenase (IDH1) gene and the vascular endothelial growth factor (VEGF) +936 C/T polymorphism in brain tumors. The impact of these genetic alterations on overall survival (OS) and progression free survival (PFS) was evaluated.MethodsA cohort of 80 patients surgically treated at Hospital Clínico San Carlos, Madrid, between March 2004 and November 2012, was analyzed. Tumors were distributed in 73 primary brain tumors (gliomas, meningiomas, hemangiopericytomas and hemangioblastomas) and seven secondary tumors evolved from a low grade glioma, thus providing a mixed sample.Results IDH1 R132H gene mutation was found in 12 patients (15%) and appears more frequently in secondary tumors (5 (71.4%) whereas in 7 (9.7%) primary tumors (p < .001)). The mutation is related to WHO grade II in primary tumors and a supratentorial location in secondary tumors. The OS analysis for IDH1 showed a tendency towards a better prognosis of the tumors containing the mutation (p = .059).The IDH1 R132H mutation confers a better PFS (p = .025) on primary tumors. The T allele of VEFG +936 C/T polymorphism was found in 16 patients (20%). No relation was found between this polymorphism and primary or secondary tumor, neither with OS or PFS.Conclusions IDH1 R132H gene mutation is exclusive in supratentorial tumors and more frequent in secondary ones, with a greater survival trend and better PFS in patients who carry it. The T allele of VEGF +936 C/T polymorphism is more common in primary tumors, although there is no statistical relation with survival.

show abstract

Hypoxia, NSAIDs, and autism: A biocultural analysis of stressors in gametogenesis

Burke

2024

American J Hum Biol

View full text Add to dashboard Cite

Cultural and generational trends have increasingly favored “anti‐inflammatory” action, innovating a new class of analgesic, non‐steroidal anti‐inflammatory drugs (NSAIDs) in the 20th century. The modern human body has been molded over evolutionary time and while acknowledging inflammation can be pathologically entwined, it also serves an important role in healthy folliculogenesis and ovulation, shaping cues that drive needed vascular change. This review argues that because of anti‐inflammatory action, the cultural invention of NSAIDs represents a particular stressor on female reproductive‐age bodies, interacting with natural, underlying variation and placing limits on healthy growth and development in the follicles, creating potential autism risk through hypoxia and mutagenic or epigenetic effects. Since testes are analogs to ovaries, the biological grounding extends naturally to spermatogenesis. This review suggests the introduction of over‐the‐counter NSAIDs in the 1980s failed to recognize the unique functioning of reproductive‐age bodies, challenging the cyclical inflammation needed for healthy gamete development. NSAIDs are framed as one (notable) stressor in an anti‐inflammatory era focused on taming the risks of inflammation in modern human life.

show abstract

Identification of Polymorphisms Within the Vascular Endothelial Growth Factor (Vegf) Gene: Correlation With Variation in Vegf Protein Production

Cited by 662 publications

References 12 publications

The vascular endothelial growth factor (VEGF) +405 G/C polymorphism and its relationship with recurrent implantation failure in women in an IVF programme with ICSI

The vascular endothelial growth factor (VEGF) +405 G/C polymorphism and its relationship with recurrent implantation failure in women in an IVF programme with ICSI

Genetic alterations of IDH1 and Vegf in brain tumors

Hypoxia, NSAIDs, and autism: A biocultural analysis of stressors in gametogenesis

Contact Info

Product

Resources

About